Metformin causes a futile intestinal–hepatic cycle which increases energy expenditure and slows down development of a type 2 diabetes-like state

Molecular Metabolism

Volumn 6, Issue 7, 2017, Pages 737-747

  Schommers, Philipp ^a,b   Thurau, Anna ^a   Bultmann Mellin, Insa ^b   Guschlbauer, Maria ^b   Klatt, Andreas R ^b   Rozman, Jan ^c,d   Klingenspor, Martin ^c,d,e   de Angelis, Martin Hrabe ^c,d   Alber, Jens ^f   Gründemann, Dirk ^a   Sterner Kock, Anja ^b   Wiesner, Rudolf J ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^c INSTITUTE OF EPIDEMIOLOGY   (Germany)

^d GERMAN CENTER FOR DIABETES RESEARCH DZD   (Germany)

^e TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^f MAX PLANCK INSTITUTE FOR NEUROLOGICAL RESEARCH   (Germany)

Author keywords

Futile cycle; Metformin; Mitochondria; Splanchnic bed

Indexed keywords

CARBON 13; GLUCOSE; GLUCOSE 1 PHOSPHATE; GLUCOSE 1,6 BISPHOSPHATE; HEMOGLOBIN A1C; LACTIC ACID; METFORMIN; ANTIDIABETIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BROWN ADIPOSE TISSUE; CONTROLLED STUDY; DRUG MECHANISM; ENERGY EXPENDITURE; FOOD INTAKE; GLUCONEOGENESIS; GLUCOSE TOLERANCE; GLYCEMIC CONTROL; INTESTINE WALL; LIPID DIET; LIPID METABOLISM; LOCOMOTION; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PORTAL VEIN BLOOD; PRIORITY JOURNAL; WEIGHT GAIN; WEIGHT REDUCTION; ANIMAL; BLOOD; C57BL MOUSE; DRUG EFFECT; ENERGY METABOLISM; INTESTINE; LIVER; METABOLISM;

ANIMALS; DIABETES MELLITUS, TYPE 2; DIET, HIGH-FAT; ENERGY METABOLISM; GLUCOSE; HYPOGLYCEMIC AGENTS; INTESTINES; LACTIC ACID; LIVER; MALE; METFORMIN; MICE; MICE, INBRED C57BL;

EID: 85019628788     PISSN: None     EISSN: 22128778     Source Type: Journal    
DOI: 10.1016/j.molmet.2017.05.002     Document Type: Article

References (55)

1. ADA, (5) Prevention or delay of type 2 diabetes. Diabetes Care 38:Suppl (2015), S31–S32.
2. Inzucchi, S.E., Bergenstal, R.M., Buse, J.B., Diamant, M., Ferrannini, E., Nauck, M., et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 55 (2012), 1577–1596.
3. Warren, R.E., The stepwise approach to the management of type 2 diabetes. Diabetes Research and Clinical Practice, 65(Supplement), 2004, S3.
4. Chilton, M., Dunkley, A., Carter, P., Davies, M.J., Khunti, K., Gray, L.J., The effect of antiobesity drugs on waist circumference: a mixed treatment comparison. Diabetes Obesity & Metabolism 16 (2014), 237–247.
5. Domecq, J.P., Prutsky, G., Leppin, A., Sonbol, M.B., Altayar, O., Undavalli, C., et al. Clinical review: drugs commonly associated with weight change: a systematic review and meta-analysis. The Journal of Clinical Endocrinology and Metabolism 100 (2015), 363–370.
6. Chappell, J.B., The effect of Alkylguanidines on mitochondrial metabolism. Journal of Biological Chemistry 238 (1963), 410–417.
7. Owen, M.R., Doran, E., Halestrap, A.P., Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochemical Journal 348:Pt 3 (2000), 607–614.
8. El-Mir, M.-Y., Nogueira, Vr, Fontaine, E., Avéret, N., Rigoulet, M., Leverve, X., Dimethylbiguanide inhibits cell respiration via an Indirect effect targeted on the respiratory chain complex I. Journal of Biological Chemistry 275 (2000), 223–228.
9. Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., et al. Role of AMP-activated protein kinase in mechanism of metformin action. The Journal of Clinical Investigation 108 (2001), 1167–1174.
10. Foretz, M., Hebrard, S., Leclerc, J., Zarrinpashneh, E., Soty, M., Mithieux, G., et al. Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. The Journal of Clinical Investigation 120 (2010), 2355–2369.
11. Pernicova, I., Korbonits, M., Metformin–mode of action and clinical implications for diabetes and cancer. Nature Reviews Endocrinology 10 (2014), 143–156.
12. Miller, R.A., Chu, Q., Xie, J., Foretz, M., Viollet, B., Birnbaum, M.J., Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP. Nature 494 (2013), 256–260.
13. Madiraju, A.K., Erion, D.M., Rahimi, Y., Zhang, X.M., Braddock, D.T., Albright, R.A., et al. Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. Nature 510 (2014), 542–546.
14. Duca, F.A., Cote, C.D., Rasmussen, B.A., Zadeh-Tahmasebi, M., Rutter, G.A., Filippi, B.M., et al. Metformin activates a duodenal Ampk-dependent pathway to lower hepatic glucose production in rats. Nature Medicine 21 (2015), 506–511.
15. Rena, G., Pearson, E.R., Sakamoto, K., Molecular mechanism of action of metformin: old or new insights?. Diabetologia 56 (2013), 1898–1906.
16. Fullerton, M.D., Galic, S., Marcinko, K., Sikkema, S., Pulinilkunnil, T., Chen, Z.P., et al. Single phosphorylation sites in Acc1 and Acc2 regulate lipid homeostasis and the insulin-sensitizing effects of metformin. Nature Medicine 19 (2013), 1649–1654.
17. Molloy, A.M., Ardill, J., Tomkin, G.H., The effect of metformin treatment on gastric acid secretion and gastrointestinal hormone levels in normal subjects. Diabetologia 19 (1980), 93–96.
18. Wilcock, C., Bailey, C.J., Accumulation of metformin by tissues of the normal and diabetic mouse. Xenobiotica 24 (1994), 49–57.
19. Bailey, C.J., Wilcock, C., Scarpello, J.H.B., Metformin and the intestine. Diabetologia 51 (2008), 1552–1553.
20. Penicaud, L., Hitier, Y., Ferre, P., Girard, J., Hypoglycaemic effect of metformin in genetically obese (fa/fa) rats results from an increased utilization of blood glucose by intestine. Biochemical Journal 262 (1989), 881–885.
21. Marella, M., Seo, B.B., Thomas, B.B., Matsuno-Yagi, A., Yagi, T., Successful amelioration of mitochondrial optic neuropathy using the yeast NDI1 gene in a rat animal model. PLoS One, 5, 2010, e11472.
22. Jensen, E.C., Quantitative analysis of histological staining and fluorescence using ImageJ. Anatomical Record (Hoboken) 296 (2013), 378–381.
23. Schneider, C.A., Rasband, W.S., Eliceiri, K.W., NIH Image to ImageJ: 25 years of image analysis. Nature Methods 9 (2012), 671–675.
24. Schindelin, J., Arganda-Carreras, I., Frise, E., Kaynig, V., Longair, M., Pietzsch, T., et al. Fiji: an open-source platform for biological-image analysis. Nature Methods 9 (2012), 676–682.
25. Tai, M.M., A mathematical model for the determination of total area under glucose tolerance and other metabolic curves. Diabetes Care 17 (1994), 152–154.
26. Reagan-Shaw, S., Nihal, M., Ahmad, N., Dose translation from animal to human studies revisited. The FASEB Journal 22 (2008), 659–661.
27. Nathan, D.M., Buse, J.B., Davidson, M.B., Ferrannini, E., Holman, R.R., Sherwin, R., et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of diabetes. Diabetes Care 32 (2009), 193–203.
28. Golay, A., Metformin and body weight. International Journal of Obesity (Lond) 32 (2008), 61–72.
29. Meneghini, L.F., Orozco-Beltran, D., Khunti, K., Caputo, S., Damci, T., Liebl, A., et al. Weight beneficial treatments for type 2 diabetes. The Journal of Clinical Endocrinology and Metabolism 96 (2011), 3337–3353.
30. Franko, A., von Kleist-Retzow, J.C., Bose, M., Sanchez-Lasheras, C., Brodesser, S., Krut, O., et al. Complete failure of insulin-transmitted signaling, but not obesity-induced insulin resistance, impairs respiratory chain function in muscle. Journal of Molecular Medicine (Berlin, Germany) 90 (2012), 1145–1160.
31. Hanas, R., John, G., on behalf of the International Hb AcCC. Consensus statement on the worldwide standardization of the hemoglobin A1c measurement. Diabetic Medicine, 27, 2010, 737.
32. Li, Yongguo, Laser, David, Fromme, Tobias, Klingenspor, Martin, White, brite, and brown adipocytes: the evolution and function of a heater organ in mammals. Canadian Journal of Zoology 92:7 (2014), 615–626.
33. Klingenspor, M., Ivemeyer, M., Wiesinger, H., Haas, K., Heldmaier, G., Wiesner, R.J., Biogenesis of thermogenic mitochondria in brown adipose tissue of Djungarian hamsters during cold adaptation. Biochemical Journal 316:Pt 2 (1996), 607–613.
34. He, L., Wondisford, F.E., Metformin action: concentrations matter. Cell Metabolism 21 (2015), 159–162.
35. Stumvoll, M., Nurjhan, N., Perriello, G., Dailey, G., Gerich, J.E., Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. The New England Journal of Medicine 333 (1995), 550–554.
36. Glueck, C.J., Fontaine, R.N., Wang, P., Subbiah, M.T., Weber, K., Illig, E., et al. Metformin reduces weight, centripetal obesity, insulin, leptin, and low-density lipoprotein cholesterol in nondiabetic, morbidly obese subjects with body mass index greater than 30. Metabolism 50 (2001), 856–861.
37. Salpeter, S.R., Buckley, N.S., Kahn, J.A., Salpeter, E.E., Meta-analysis: metformin treatment in persons at risk for diabetes mellitus. The American Journal of Medicine 121 (2008), 149–157 e2.
38. Bridges, H.R., Jones, A.J., Pollak, M.N., Hirst, J., Effects of metformin and other biguanides on oxidative phosphorylation in mitochondria. Biochemical Journal 462 (2014), 475–487.
39. Bailey, C.J., Wilcock, C., Day, C., Effect of metformin on glucose metabolism in the splanchnic bed. British Journal of Pharmacology 105 (1992), 1009–1013.
40. Vidon, N., Chaussade, S., Noel, M., Franchisseur, C., Huchet, B., Bernier, J.J., Metformin in the digestive tract. Diabetes Research and Clinical Practice 4 (1988), 223–229.
41. Dujic, T., Zhou, K., Donnelly, L.A., Tavendale, R., Palmer, C.N., Pearson, E.R., Association of organic cation transporter 1 with intolerance to metformin in type 2 diabetes: a GoDARTS study. Diabetes 64 (2015), 1786–1793.
42. Berg, J.M., Stryer, L., Tymoczko, J.L., Stryer biochemie. 2013, Springer Spektrum.
43. Halestrap, A.P., Wilson, M.C., The monocarboxylate transporter family–role and regulation. IUBMB Life 64 (2012), 109–119.
44. Markert, C.L., Shaklee, J.B., Whitt, G.S., Evolution of a gene. Multiple genes for LDH isozymes provide a model of the evolution of gene structure, function and regulation. Science 189 (1975), 102–114.
45. Shu, Y., Sheardown, S.A., Brown, C., Owen, R.P., Zhang, S., Castro, R.A., et al. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. The Journal of Clinical Investigation 117 (2007), 1422–1431.
46. Nakamichi, N., Shima, H., Asano, S., Ishimoto, T., Sugiura, T., Matsubara, K., et al. Involvement of carnitine/organic cation transporter OCTN1/SLC22A4 in gastrointestinal absorption of metformin. Journal of Pharmaceutical Sciences 102 (2013), 3407–3417.
47. Wilcock, C., Bailey, C.J., Sites of metformin-stimulated glucose metabolism. Biochemical Pharmacology 39 (1990), 1831–1834.
48. Zhou, M., Xia, L., Wang, J., Metformin transport by a newly cloned proton-stimulated organic cation transporter (plasma membrane monoamine transporter) expressed in human intestine. Drug Metabolism and Disposition: The Biological Fate of Chemical 35 (2007), 1956–1962.
49. Han, T.K., Proctor, W.R., Costales, C.L., Cai, H., Everett, R.S., Thakker, D.R., Four cation-selective transporters contribute to apical uptake and accumulation of metformin in Caco-2 cell monolayers. The Journal of Pharmacology Experimental Therapeutics 352 (2015), 519–528.
50. Graham, G.G., Punt, J., Arora, M., Day, R.O., Doogue, M.P., Duong, J.K., et al. Clinical pharmacokinetics of metformin. Clinical Pharmacokineticts 50 (2011), 81–98.
51. DeFronzo, R., Fleming, G.A., Chen, K., Bicsak, T.A., Metformin-associated lactic acidosis: current perspectives on causes and risk. Metabolism 65 (2016), 20–29.
52. Buse, J.B., DeFronzo, R.A., Rosenstock, J., Kim, T., Burns, C., Skare, S., et al. The primary glucose-lowering effect of metformin resides in the gut, not the circulation: results from short-term pharmacokinetic and 12-week dose-ranging studies. Diabetes Care 39 (2016), 198–205.
53. Forslund, K., Hildebrand, F., Nielsen, T., Falony, G., Le Chatelier, E., Sunagawa, S., et al. Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. Nature 528 (2015), 262–266.
54. De Vadder, F., Kovatcheva-Datchary, P., Goncalves, D., Vinera, J., Zitoun, C., Duchampt, A., et al. Microbiota-generated metabolites promote metabolic benefits via gut-brain neural circuits. Cell 156 (2014), 84–96.
55. Brunkwall, L., Orho-Melander, M., The gut microbiome as a target for prevention and treatment of hyperglycaemia in type 2 diabetes: from current human evidence to future possibilities. Diabetologia 60 (2017), 943–951.